01
May

Even as reports of a prospective takeover bid from Allergan circulate, Shire CEO Flemming Ornskov shows no sign of slowing down on the company’s deal spree. The biotech is buying Australia’s Fibrotech for $75 million upfront and a string of undisclosed milestones, bringing in a lead drug for fibrosis.

…read more

Source: Shire bags an early-stage fibrosis drug in $75M Fibrotech buyout

    

0 No comments